These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 23644232)

  • 21. The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions.
    Curatolo P; Bjørnvold M; Dill PE; Ferreira JC; Feucht M; Hertzberg C; Jansen A; Jóźwiak S; Kingswood JC; Kotulska K; Macaya A; Moavero R; Nabbout R; Zonnenberg BA
    Drugs; 2016 Apr; 76(5):551-65. PubMed ID: 26927950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of mTOR inhibitors in epilepsy treatment.
    Sadowski K; Kotulska-Jóźwiak K; Jóźwiak S
    Pharmacol Rep; 2015 Jun; 67(3):636-46. PubMed ID: 25933981
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cerebral vascular and blood brain-barrier abnormalities in a mouse model of epilepsy and tuberous sclerosis complex.
    Guo D; Zhang B; Han L; Rensing NR; Wong M
    Epilepsia; 2024 Feb; 65(2):483-496. PubMed ID: 38049961
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of mTOR signalling in neurogenesis, insights from tuberous sclerosis complex.
    Tee AR; Sampson JR; Pal DK; Bateman JM
    Semin Cell Dev Biol; 2016 Apr; 52():12-20. PubMed ID: 26849906
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epileptogenesis in tuberous sclerosis complex-related developmental and epileptic encephalopathy.
    Aronica E; Specchio N; Luinenburg MJ; Curatolo P
    Brain; 2023 Jul; 146(7):2694-2710. PubMed ID: 36806388
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Finding a better drug for epilepsy: the mTOR pathway as an antiepileptogenic target.
    Galanopoulou AS; Gorter JA; Cepeda C
    Epilepsia; 2012 Jul; 53(7):1119-30. PubMed ID: 22578218
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rapamycin: one drug, many effects.
    Li J; Kim SG; Blenis J
    Cell Metab; 2014 Mar; 19(3):373-9. PubMed ID: 24508508
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic Etiologies, Diagnosis, and Treatment of Tuberous Sclerosis Complex.
    Salussolia CL; Klonowska K; Kwiatkowski DJ; Sahin M
    Annu Rev Genomics Hum Genet; 2019 Aug; 20():217-240. PubMed ID: 31018109
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacological inhibition of the mammalian target of rapamycin pathway suppresses acquired epilepsy.
    Huang X; Zhang H; Yang J; Wu J; McMahon J; Lin Y; Cao Z; Gruenthal M; Huang Y
    Neurobiol Dis; 2010 Oct; 40(1):193-9. PubMed ID: 20566381
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A circuitry and biochemical basis for tuberous sclerosis symptoms: from epilepsy to neurocognitive deficits.
    Feliciano DM; Lin TV; Hartman NW; Bartley CM; Kubera C; Hsieh L; Lafourcade C; O'Keefe RA; Bordey A
    Int J Dev Neurosci; 2013 Nov; 31(7):667-78. PubMed ID: 23485365
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic value of prenatal rapamycin treatment in a mouse brain model of tuberous sclerosis complex.
    Anderl S; Freeland M; Kwiatkowski DJ; Goto J
    Hum Mol Genet; 2011 Dec; 20(23):4597-604. PubMed ID: 21890496
    [TBL] [Abstract][Full Text] [Related]  

  • 32. mTOR pathway inhibition as a new therapeutic strategy in epilepsy and epileptogenesis.
    Citraro R; Leo A; Constanti A; Russo E; De Sarro G
    Pharmacol Res; 2016 May; 107():333-343. PubMed ID: 27049136
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is mTOR inhibition a systemic treatment for tuberous sclerosis?
    Moavero R; Coniglio A; Garaci F; Curatolo P
    Ital J Pediatr; 2013 Sep; 39():57. PubMed ID: 24044547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tuberous sclerosis complex as a model disease for developing new therapeutics for epilepsy.
    Jeong A; Wong M
    Expert Rev Neurother; 2016; 16(4):437-47. PubMed ID: 26854692
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular therapies for tuberous sclerosis and neurofibromatosis.
    Franz DN; Weiss BD
    Curr Neurol Neurosci Rep; 2012 Jun; 12(3):294-301. PubMed ID: 22544507
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mammalian target of rapamycin (mTOR) as a potential therapeutic target in various diseases.
    Kaur A; Sharma S
    Inflammopharmacology; 2017 Jun; 25(3):293-312. PubMed ID: 28417246
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis.
    Franz DN
    Expert Rev Anticancer Ther; 2011 Aug; 11(8):1181-92. PubMed ID: 21916571
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The mTOR signalling cascade: paving new roads to cure neurological disease.
    Crino PB
    Nat Rev Neurol; 2016 Jul; 12(7):379-92. PubMed ID: 27340022
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current Use of mTOR Inhibitors for the Treatment of Subependymal Giant Cell Astrocytomas and Epilepsy in Patients with TSC.
    Jancic J; Duric V; Ivancevic N; Nikolic B; van den Anker JN; Samardzic J
    Curr Med Chem; 2016; 23(37):4260-4269. PubMed ID: 27739368
    [TBL] [Abstract][Full Text] [Related]  

  • 40. mTOR dysregulation and tuberous sclerosis-related epilepsy.
    Curatolo P; Moavero R; van Scheppingen J; Aronica E
    Expert Rev Neurother; 2018 Mar; 18(3):185-201. PubMed ID: 29338461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.